Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc.
301 Binney Street
Cambridge, MA 02142
Phone: (617) 621 7722Website: https://www.ironwoodpharma.comCareers: www.ironwoodpharma.com/join-us
Latest news
- Ironwood Pharmaceuticals Announces FDA Approval of New Indication for Linzess (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
12 June 2023 - FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout
21 August 2017 - U.S. FDA Approves 72 mcg Dose of Linzess (linaclotide) for Adults with Chronic Idiopathic Constipation
26 January 2017 - Ironwood Announces New Drug Application for Duzallo (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
4 January 2017 - FDA Approves Zurampic (lesinurad) to Treat High Blood Uric Acid Levels Associated with Gout
22 December 2015 - FDA Advisory Committee Recommends the Approval of Lesinurad for Gout Patients
23 October 2015 - FDA Approves Linzess to Treat Certain Cases of Irritable Bowel Syndrome and Constipation
30 August 2012 - Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide
8 February 2012 - Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review
24 October 2011 - Ironwood and Forest Announce Submission of New Drug Application for Linaclotide for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation
9 August 2011
Drugs Associated with Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Brand/Generic Name | Reviews | Rating |
---|---|---|
Linzess
Generic name: linaclotide Drug class: guanylate cyclase-C agonists |
778 reviews | 6.6 / 10 |
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |